Abstract
The paper presents a clear survey of trends in incidence and mortality for ovarian cancer, following from recent statistical data. It summarizes the present diagnostic possibilities, the used prognostic factors and treatment schemes.
A special attention is given to treatment. The treatment of persistent or relapsing illness, where significant progress has been achieved during the past 20 years by introducing bevacizumab, a new drug used in combination with carboplatin and paclitaxel.
This treatment scheme is indicated as initial treatment of an advanced (III B, III C and IV stages according to FIGO) ovarian epithelial cancer, Fallopian tube cancer or primary peritoneal cancer. This scheme is becoming a new standard of care of patients with an advanced ovarian cancer.
